With the introduction of immunotherapies such as anti-PD1, which has shown excellent clinical efficacy in a subset of CRC patients, there has never been a stronger incentive to incorporate PDEs in future preclinical studies. The gene discussed is PDCD1; the disease is colorectal carcinoma.